Impfungen gegen humanes Papillomavirus – Sind sie für Mädchen und Jungen gleich sinnvoll?

Etwa 20 % aller Krebserkrankungen hängen mit viralen Infektionenzusammen. Wie wirksam sind entsprechende Impfungen, und lassen sie sich weltweit flächendeckend durchführen?

• Literatur

• 1 Martel C, Ferlay J, Franceschi S et al. The global burden of cancers attributable to infections in the year 2008. Lancet Oncol 2012; 13: 607-615
• 2 Bosch FX, Lorincz A, Munoz N et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265
• 3 zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 1994; 186: 131-156
• 4 Bouvard V, Baan R, Straif K et al. A review of human carcinogens. B. Biological agents. Lancet Oncol 2009; 10: 321-322
• 5 de Sanjose S, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-1056
• 6 Giuliano AR, Tortolero-Luna G, Ferrer E et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008; 26 (Suppl. 10) 17-28
• 7 De Vuyst H, Clifford GM, Nascimento MC et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124: 1626-1636
• 8 Backes DM, Kurman RJ, Pimenta JM et al. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009; 20: 449-457
• 9 Garland SM, Cuzick J, Domingo EJ et al. Recommendations for cervical cancer prevention in Asia Pacific. Vaccine 2009; 26 (Suppl. 12) 89-98
• 10 Moscicki AB, Schiffman M, Kjaer S et al. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24 (Suppl. 03) 42-51
• 11 Moscicki A, Schiffman M, Burchell A et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012; 30 (Suppl. 05) 24-33
• 12 Bosch FX, Tsu V, Vorsters A et al. Reframing Cervical Cancer Prevention. Expanding the Field Towards Prevention of Human Papillomavirus Infections and Related Diseases. Vaccine 2012; 30
• 13 Cuzick J, Arbyn M, Sankaranarayanan R et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26 (Suppl. 10) 29-41
• 14 Schiller JT, Castellsague X, Villa LL et al. An update of prophylactic human papillomavirus L1 virus. Vaccine 2008; 26 (Suppl. 10) 53-61
• 15 Schiller J, Castellsagué X, Garland S. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 (Suppl. 05) 123-138
• 16 Palefsky JM, Giuliano AR, Goldstone S et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365: 1576-1585
• 17 Munoz N, Kjaer SK, Sigurdsson K et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-339
• 18 Giuliano AR, Palefsky JM, Goldstone S et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364: 401-411
• 19 Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943
• 20 Palefsky JM, Giuliano AR, Goldstone S et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365: 1576-1585
• 21 Insinga RP, Dasbacha E, Elbashaa E, Puigb A Reynales-Shigematsuc Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007; 26: 128-139
• 22 European Centre for Disease Prevention and Control (ECDC). Guidance for the introduction of HPV vaccines European countries. 2008
• 23 Bingham A, Drake JK, LaMontagne DS. Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings. Arch Pediatr Adolesc Med 2009; 163: 455-461
• 24 Biellik R, Levin C, Mugisha E et al. Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Vaccine 2009; 27: 6203-6209
• 25 Tsu V, Murray M. Limited benefit of HPV vaccination for sexually active women in developing countries. Vaccine 2011; 29: 9290-9291
• 26 PATH Rho Cervical Cancer, 2012. Im Internet: http://www.rho.org Stand: November 2013